Pepaxti has been granted Marketing Authorization in the European Union, including the EEA-countries Iceland, Lichtenstein and Norway, by the European Commission on August 18, 2022. The product was approved by the Medicines and Healthcare Products Regulatory Agency, MHRA, in the UK on November 11, 2022.
Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
Oncopeptides has submitted a type II variation for Pepaxti to the European Medicines Agency (EMA), to enable use in one earlier treatment line. The submission is based on data from the phase 3 OCEAN study.
On December 7, 2022, the US Food and Drug Administration, FDA, requested Oncopeptides to withdraw the US marketing authorization for Pepaxto. At FDA’s request, Oncopeptides stopped marketing Pepaxto in the US on October 22, 2021, and the drug is currently not commercially available for patients.
Pepaxto was granted accelerated approval in the U.S., on February 26, 2021, and is indicated in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
Pepaxto was voluntarily withdrawn from the US market on October 22, 2021. The withdrawal was rescinded on January 21, 2022, based on further review and analyses of the heterogenous Overall Survival data from the OCEAN study and other relevant studies.